{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:15:52Z","timestamp":1774548952326,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.lungcan.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T02:42:25Z","timestamp":1549766545000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0324-1363","authenticated-orcid":false,"given":"Tamkin","family":"Ahmadzada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy A","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Linton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-4693","authenticated-orcid":false,"given":"Rebecca","family":"Asher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-1222","authenticated-orcid":false,"given":"Stephen","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-5223","authenticated-orcid":false,"given":"Glen","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.02.005_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2017.11.015","article-title":"Progress and challenges in Mesothelioma: from bench to bedside","volume":"134","author":"Blyth","year":"2018","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.005_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010238","article-title":"Heterogeneous contributing factors in MPM disease development and progression: biological advances and clinical implications","volume":"19","author":"Tolani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.lungcan.2019.02.005_bib0015","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.005_bib0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: the standard of care and challenges for future management","volume":"78","author":"van Meerbeeck","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"Suppl 9","key":"10.1016\/j.lungcan.2019.02.005_bib0025","article-title":"Biomarkers in malignant pleural mesothelioma: current status and future directions","volume":"10","author":"Ahmadzada","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.005_bib0030","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.005_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4161\/cam.4.1.11361","article-title":"What\u2019s the place of immunotherapy in malignant mesothelioma treatments?","volume":"4","author":"Gr\u00e9goire","year":"2010","journal-title":"Cell Adh. Migr."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.005_bib0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2019.02.005_bib0045","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2019.02.005_bib0050","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000312","article-title":"BIN1 localizes the L-type calcium channel to cardiac T-tubules","volume":"8","author":"Hong","year":"2010","journal-title":"PLoS Biol."},{"issue":"12","key":"10.1016\/j.lungcan.2019.02.005_bib0060","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/cdd.2009.98","article-title":"The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage","volume":"16","author":"Cassimere","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.freeradbiomed.2013.10.003","article-title":"Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans","volume":"67","author":"Stapelberg","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000002754","article-title":"IDO1 expression is associated with immune tolerance and poor prognosis in patients with surgically resected esophageal Cancer","author":"Kiyozumi","year":"2018","journal-title":"Ann. Surg."},{"issue":"13","key":"10.1016\/j.lungcan.2019.02.005_bib0075","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ejca.2011.09.007","article-title":"Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients","volume":"48","author":"Speeckaert","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.005_bib0080","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.29481","article-title":"Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients","volume":"137","author":"Jia","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.02.005_bib0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2119\/molmed.2011.00319","article-title":"Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma","volume":"18","author":"Pan","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for Cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.005_bib0095","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2010.05554.x","article-title":"Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model","volume":"1203","author":"Hillegass","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0105","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/TCRM.S104077","article-title":"Are neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?","volume":"12","author":"Tural Onur","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"issue":"6","key":"10.1016\/j.lungcan.2019.02.005_bib0110","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.lungcan.2019.02.005_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70126-2","article-title":"Immunotherapies for non-small-cell lung cancer and mesothelioma","volume":"13","author":"Thomas","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2019.02.005_bib0120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.lungcan.2019.02.005_bib0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.005_bib0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041041","article-title":"Heterogeneity in immune cell content in malignant pleural mesothelioma","volume":"19","author":"Minnema-Luiting","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.005_bib0135","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/JTO.0b013e3182037b76","article-title":"The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on Cancer development, progression, and prognosis: emphasis on non-small cell lung Cancer","volume":"6","author":"Bremnes","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2019.02.005_bib0140","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2019.02.005_bib0145","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.lungcan.2019.02.005_bib0155","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-011-1073-8","article-title":"Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients","volume":"60","author":"Suzuki","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.005_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"7637","key":"10.1016\/j.lungcan.2019.02.005_bib0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.lungcan.2019.02.005_bib0170","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.005_bib0175","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2019.02.005_bib0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ng0996-69","article-title":"BIN1 is a novel MYC\u2013interacting protein with features of a tumour suppressor","volume":"14","author":"Sakamuro","year":"1996","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.005_bib0185","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/(SICI)1097-0215(20000201)85:3<376::AID-IJC14>3.0.CO;2-1","article-title":"Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity","volume":"85","author":"Ge","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"17","key":"10.1016\/j.lungcan.2019.02.005_bib0190","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.1073\/pnas.96.17.9689","article-title":"Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma","volume":"96","author":"Ge","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.005_bib0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.005_bib0200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1389450114666140106095151","article-title":"Targeting tumor suppressor networks for cancer therapeutics","volume":"15","author":"Guo","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"12","key":"10.1016\/j.lungcan.2019.02.005_bib0205","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/bies.201500093","article-title":"Targeting tumor suppressor genes for cancer therapy","volume":"37","author":"Liu","year":"2015","journal-title":"Bioessays"},{"issue":"45","key":"10.1016\/j.lungcan.2019.02.005_bib0210","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1038\/onc.2017.217","article-title":"BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR\/MAPK signaling pathways in non-small cell lung cancer","volume":"36","author":"Wang","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.lungcan.2019.02.005_bib0215","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/jcmm.13593","article-title":"Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma","volume":"22","author":"Hsu","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.03.001","article-title":"Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"96","author":"Cedres","year":"2016","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.005_bib0225","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0230","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2119\/molmed.2012.00029","article-title":"Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase","volume":"18","author":"Orabona","year":"2012","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.005_bib0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bcpt.12320","article-title":"The targeting of indoleamine 2,3 dioxygenase -Mediated immune escape in Cancer","volume":"116","author":"Iversen","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.lungcan.2019.02.005_bib0240","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3(+) t cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the Anti-PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum. Pathol."},{"issue":"12","key":"10.1016\/j.lungcan.2019.02.005_bib0250","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic t cells in PD-L1-Positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.005_bib0255","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2019.02.005_bib0260","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.005_bib0265","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2019.02.005_bib0270","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.005_bib0275","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.005_bib0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J. Surg. Res."},{"issue":"26","key":"10.1016\/j.lungcan.2019.02.005_bib0285","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"South Afr. Med. J."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.005_bib0290","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12199-016-0530-6","article-title":"Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Tanrikulu","year":"2016","journal-title":"Environ. Health Prev. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T17:29:25Z","timestamp":1662917365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219303101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":58,"alternative-id":["S0169500219303101"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}